drugset / Trial / NCT02129881

The ONE Study UK Treg Trial

NCT02129881

NaSingle-groupOpen-labelTreatment

Summary

A study to assess cell therapy as a treatment to prevent kidney transplant rejection. The trial will involve purification of naturally occurring regulatory T cells (nTregs) from living-donor renal transplant recipients. The cells will then be grown in the laboratory and re-infused into the patient five days after the kidney transplant. This trial is part of an international European Union funded consortium aimed at evaluating cellular immunotherapy in solid organ transplantation (The ONE Study). It is anticipated that immune regulation induced by nTreg therapy can eventually be used to recude the need for conventional immunosuppression in transplant recipients.

Timeline

Start
2014-04
Primary completion
2017-03-23
Completion
2017-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous regulatory T Cell Product Cell therapy Intravenous